BlueRock Therapeutics

Subsidiary of Bayer (BAYN)

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Midbrain dopaminergic neuronsCell therapy
Parkinson's Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
October 2028 (1)
Bemdaneprocel (MSK-DA01)Phase 3Parkinsons Disease (PD)
Est. primary completion 2028-10 · NCT06944522 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.